Description: This substantive book is a compilation of focused reviews and laboratory protocols for biomarkers associated with melanoma and related targeted therapies.
Purpose: The purpose is to "provide updated information on well-characterized diagnostic and prognostic assays and assays predicting response to treatment for routine testing." These are worthy objectives in this rapidly evolving area, well met by this book.
Audience: This would be useful to anyone interested in melanoma, from clinicians wanting an update on promising molecular targets for melanoma treatment to researchers wanting detailed protocols for diagnostic or treatment monitoring assays. The authors are quite credible authorities in their fields.
Features: This somewhat hefty (712 pages) book covers the breadth and depth of melanoma in 37 chapters comprising seven sections. It starts with a succinct review of clinical challenges and the current treatment of melanoma. Subsequent sections cover various biomarkers useful for estimating response to treatment, classification, diagnosis, and prognosis. An entire section is devoted to uveal melanoma. The last three sections discuss emerging markers or targets, technologies for marker validation, and (most important in my opinion) validation requirements for clinical application. True to the nature of Springer Protocols, this book is full of detailed laboratory protocols, easy to follow and ready to implement. Many are accompanied by exemplary photographs of the expected results. As an example of the considerable detail, the preface alone is nine pages and written in conventional scientific style, including an abstract(!).
Assessment: If you are working in melanoma research or treating patients with melanoma, you will very much appreciate this book.